National Academies advisory: Invasive aquatic species in the Great Lakes
On May 7, a National Research Council committee will hold a meeting in Toronto to gather information on trade in the Great Lakes region and ways to eliminate further introductions of nonindigenous aquatic species into the lakes by vessels traveling the St. Lawrence Seaway. The committee's final report will comment on the strengths and weaknesses of various options and recommend those that seem mo...Tapping the value of entrepreneurial advisors
In a discussion moderated by my colleague, Matthew Sto...Tommy Thompson joins drug company as advisor
Tommy Tompson, formerly a Wisconsin governor and then secretary of the U.S. Department of Health and Human Services, has accepted an advisory position with Alfacell Corporation. Alfacell develops cancer theraputics and is moving closer to filing a new drug application with the federal Food and Drug Administration for its lead drug candidate. The company's headquarters are in Bloomfield,...Federal advisor to HHS describes the national information infrastructure
MADISON In a speech given April 27, President Bush proclaimed that health care in America is in desperate need of aid, citing a 21st century health care system [which] uses a 19th century paperwork system. While this seems to be a grim statement, Dr. William Yasnoff , a physician and computer scientist who serves as senior advisor for the N...Quintessence Biosciences forms cancer therapeutic advisory board
MADISON Announced last week by President and Chief Executive Officer , the board will consist of distinguished...GenTel Appoints Burke to its Scientific Advisory Board
MADISON, Wis. October 17, 2003. GenTel BioSurfaces, Inc., a privately held UWMadison biotechnology spin-off, announced today that it has appointed Thomas J. Burke, Ph.D., to its Scientific Advisory Board. "Tom's extensive scientific experience, as well as his demonstrated expertise in grant writing, intellectual property management, and new product development make him ideally suited to...FDA Issues Public Health Advisory on Tysabri, a New Drug for MS
The Food and Drug Administration (FDA) today issued a public health advisory to inform patients and health care // providers about the suspended marketing of Tysabri (nataluzimab) while the agency and the manufacturer evaluate two serious adverse events reported with its use. Tysabri, which received accelerated approval from FDA in November 2004, is an innovative treatment that repre...Doctors Said – ‘Stop Pressurising NHS Advisory Bod’
The NICE (National Institute for Health and Clinical Excellence) carried out study regarding whether if new drugs and technologies are cost effective or not//....Merck's Pain Reliever Arcoxia Rejected by US Federal Advisory Panel
An advisory panel of the United States Food and Drug Administration (FDA) has rejected pharmaceutical giant Merck's bid to market Arcoxia,// a new osteoarthritis medication following concerns that it may carry cardiovascular risks. Osteoarthritis is a joint disease that mostly affects cartilage. Cartilage is the slippery tissue that covers the ends of bones in a joint. Whil...FDA Advisory Against Anti-depressants to Be Expanded to Cover Young Adults too
Anti-depressants could indeed lift one out of depression. But its potential to drive teenagers to suicide has already been recognized//. Now the U.S. Food and Drug Administration (FDA) has proposed that makers of all antidepressant medications update the existing black box warning on their products' labeling to include warnings about increased risks of suicidal thinking and behavior,...FDA Announces Change of Location Notice for Upcoming Advisory Committee Meeting
ROCKVILLE, Md., April 18, 2007--Due to water damage caused byflooding over the weekend, FDA has been forced to change thelocation for the upcoming Antiviral Drugs Advisory Committeemeeting on April 24, 2007 to discuss new drug application formaraviroc 300 milligram tablets. Originally scheduled to be held atthe FDA, Center for Drug Evaluation and Research Advisory CommitteeConference Roo...Media Advisory: ACC Updated Schedule
Schering-Plough Announces Presentation Of Phase II Trial ResultsFor Novel Oral Thrombin Receptor Antagonist At The 2007 AnnualMeeting Of The American College Of Cardiology/i2 Summit KENILWORTH, N.J., March 16, 2007 /PRNewswire-FirstCall/ --Schering-Plough Corporation announced today that results of thePhase II trial of its novel oral thrombin receptor antagonist (TRA)SCH 530348 will be pr...